Weather , , 0°C

Boisenews Now

Progressive Supranuclear Palsy Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Progressive Supranuclear Palsy Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

February 10
20:00 2021
Progressive Supranuclear Palsy Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Progressive Supranuclear Palsy Market

(Albany, US) DelveInsight has launched a new report on Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030.

DelveInsight’s ‘ Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Progressive Supranuclear Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Some of Progressive Supranuclear Palsy facts:

  • According to Delveinsight, prevalence of PSP was 1.89 per 100,000 and age-standardized prevalence to the US population was 2.95 per 100,000.
  • DelveInsight’s Analysts, estimated that the prevalence of PSP in the UK was 1.0 per 100,000. The age-adjusted standardized prevalence figure for PSP from this study was observed to be 5.0.
  • According to a study conducted by Kawashima et al. 2004, in Japan the prevalence of PSP was 5.82 per 100,000
  • United States has the highest percentage of prevalent diagnosed and treated patients

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market

 

Scope of Progressive Supranuclear Palsy Report:

  • The report covers the descriptive overview of Progressive Supranuclear Palsy , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Progressive Supranuclear Palsy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Progressive Supranuclear Palsy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Progressive Supranuclear Palsy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Progressive Supranuclear Palsy market

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market

 

Progressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech and swallowing.

The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low. Although PSP is not fatal, symptoms do continue to worsen and it can not be cured.

Complications that result from worsening symptoms, such as pneumonia (from breathing in food particles while choking during eating) can be life threatening. There are different subtypes of PSP which incudes, PSP with Richardson’s syndrome (PSP-RS), PSP with predominant parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP- PAGF), PSP with corticobasal syndrome (PSP-CBS), PSP with predominant language and speech dysfunction (PSP-PNFA and PSP-AOS), PSP with predominant frontotemporal dysfunction (PSP-FTD), PSP with cerebellar ataxia (PSP-C), and PSP with primary lateral sclerosis (PSP-PLS).

The only proven risk factor for PSP is age. The condition typically affects people around the age of 60, and is virtually unknown in people under the age of 40.

There’s no single test for PSP. Instead, the diagnosis is based on the pattern of the symptoms.

The large number of possible symptoms of PSP also makes it difficult to diagnose correctly and can mean it takes a while to get a definitive diagnosis. Apart from this, PSP is often misdiagnosed as Parkinson disease, Alzheimer disease, corticobasal degeneration and other neurodegenerative disorders.

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market

 

Some of Progressive Supranuclear Palsy Companies:

  • AlzProtect
  • UCB Biopharma
  • Asceneuron Therapeutics
  • TauRx Pharmaceuticals
  • And Many Others

 

Progressive Supranuclear Palsy Drugs Covered:

  • AZP2006
  • UCB0107
  • ASN120290
  • LMTX
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market

 

Table of Contents:

1 Key Insights

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

5 Disease Background and Overview

6 Epidemiology and Patient Population

7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)

8 Treatment

9 Unmet Needs

10 Emerging drugs

11 Other promising candidates

12 No development reported

13 Discontinued therapies

14 Progressive Supranuclear Palsy (PSP): Seven Major Market Analysis

15 United States

16 EU5 Countries

17 Japan

18 Market Drivers

19 Market Barriers

20 Appendix

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

Related Articles

Categories